Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Metabolic diseases

Metabolic diseases represent a growing health burden to society. Type 2 diabetes is already a major health concern, with a rapidly increasing incidence in children and young adults, much of it related to obesity. NAFLD (non-alcoholic fatty liver disease) is a broad spectrum of liver diseases with many of the same risk factors as metabolic disease including obesity, T2D, hypertension and hyperlipdeamia, whose serious health impact is increasingly big recognised.

Sygnature’s scientists have extensive experience in the field of metabolic disease, from early medicinal chemistry right through to in vivo testing. The integrated teams at Sygnature Discovery have a track record of delivering validated drug candidates to clients.

Our bioscientists have developed a wide range of metabolic disease assays across a number of platforms, including high-content imaging. We are skilled in the development of bespoke assays to meet individual project requirements. Tailored screening cascades can be created to support hit identification and lead optimisation programmes. Both tissue and blood-based biomarkers can also be evaluated in models of obesity and Type 2 diabetes.

Since 2001, our translational team has been carrying out studies for clients using a wide range of clinically validated models, both industry-standard and bespoke.

Metabolic Assays

Industry standard in vitro assays in use at Sygnature include:

  • Glucose-stimulated insulin secretion (GSIS) assays in mouse (Min6, bTC-6) and hamster (HIT-T15) cell models.
  • GLP-1 secretion assays in intestinal L cell systems (murine GLUTag cells).
  • Glucose uptake assays in adipocytes and differentiated 3T3L1 fibroblasts.

We also offer:

  • Tailored assays to probe target engagement and signalling pathways in both recombinant and immortalised cell models.
  • Models of hormone release via functional assays developed in models of pancreatic beta-cells.

Metabolic In Vivo Models

Sygnature has significant in-house in vivo experience and capabilities in the metabolic area. To see our models and how we can address your preclinical project needs, visit here.

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.

Fibrotic diseases

Sygnature Discovery’s integrated teams of medicinal chemists, bio scientists, DMPK and translational scientists have developed significant expertise in drug discovery in the fibrosis field, with a particular focus on kidney, liver and lung fibrosis.

DISCOVER

Metabolic diseases

Sygnature’s scientists have extensive experience in the field of metabolic disease, from early medicinal chemistry right through to in vivo testing. The integrated teams at Sygnature Discovery have a track record of delivering validated drug candidates to clients.

DISCOVER

Oncology and Immuno-oncology

We have successfully delivered more than 16 pre-clinical oncology projects, utilising our Integrated Drug Discovery expertise to develop small molecule drug candidates to treat a variety of cancers such as leukaemia, breast and prostate cancer. From initial screening and profiling through to clinically relevant Biomarkers, our DMPK and bioscience group can provide full support for your discovery projects.

DISCOVER

Anti-Infectives

Sygnature have a history of enabling discovery success in the field of anti-infectives. Our Integrated Drug Discovery teams have worked in close collaboration with many clients to design potent and efficacious compounds. Our Bioscience team can provide cytopathic effect and viability screening assays to assess compounds designed to inhibit virus attachment, entry or replication in human host cells.

DISCOVER

Neuroscience

Our scientists have a well-developed understanding of the challenges associated with the design and optimisation of compounds that target the central nervous system (CNS). Our experience is both broad, reaching across a number of neurodegenerative diseases (such as Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis) and neuropathic pain, and deep-rooted, with members of our senior team having 10+ years in CNS drug research.

DISCOVER

Respiratory

We have an excellent track record of success in the field of respiratory diseases using our extensive in-house expertise, accelerating 5 compounds to the clinic and a further 4 into preclinical development for our clients. Our collaborative approach to drug discovery and our established network of KOLs in the field have been invaluable to the progression of our clients’ projects

DISCOVER

Inflammation and Immunology

Our scientists have a rich heritage in this therapeutic area and provide significant experience in developing in vitro assays utilising Peripheral Blood Mononuclear Cells (PBMCs), T lymphocytes (e.g. CD4+/CD8+), leukocytes, and phagocytes, amongst others, that assess various inflammation and immunological biomarkers, processes, and endpoints.

DISCOVER